Patents by Inventor Pilar Lupon-Roses

Pilar Lupon-Roses has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solid forms of dabigatran etexilate mesylate and processes for their preparation
    Patent number: 9073899
    Abstract: It relates to solid forms of dabigatran etexilate mesylate, in particular dabigatran etexilate mesylate in crystalline Form A, and in amorphous form; to processes for their preparation, and to pharmaceutical compositions comprising them. It also relates to a crystalline form of dabigatran etexilate base (Form A), and to a process for its preparation.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: July 7, 2015
    Assignee: ESTEVE QUÍMICA, S.A.
    Inventors: Martí Bartra Sanmartí, Rosa Maria Espinosa Ferrer, Maria del Pilar Lupon Roses, Stephen Benedict David Winter, Silvia Donnici Garcia
  • SOLID FORMS OF DABIGATRAN ETEXILATE MESYLATE AND PROCESSES FOR THEIR PREPARATION
    Publication number: 20150038721
    Abstract: It relates to solid forms of dabigatran etexilate mesylate, in particular dabigatran etexilate mesylate in crystalline Form A, and in amorphous form; to processes for their preparation, and to pharmaceutical compositions comprising them. It also relates to a crystalline form of dabigatran etexilate base (Form A), and to a process for its preparation.
    Type: Application
    Filed: February 21, 2013
    Publication date: February 5, 2015
    Inventors: Martí Bartra Sanmartí, Rosa Maria Espinosa Ferrer, Maria del Pilar Lupon Roses, Stephen Benedict David Winter, Silvia Donnici Garcia
  • Polymorphs of lesopitron dihydrochloride and its hydrated forms, preparation processes and compositions containing it
    Patent number: 5872125
    Abstract: It comprises the new polymorphs I and II of Lesopitron dihydrochloride, characterized by their infrared spectra and their X-ray diffraction patterns. They are obtained by crystallization of Lesopitron dihydrochloride. It also comprises the forms I-hydrate and II-hydrate, which are obtained from the corresponding polymorphs, which have a water content from 3 to 6% and from 1.5 to 2.5%, respectively. These products are used in human medicine mainly due to their pharmacological activity over the central nervous system.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: February 16, 1999
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Pilar Lupon-Roses, Jaime Tomas-Navarro, Salvador Puig-Torres, Jordi Frigola-Constansa